# Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

> **NCT03121352** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Metastatic Triple Negative Breast Cancer

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Nab-paclitaxel
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03121352
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-19
- **Primary completion:** 2022-02-20
- **Final completion:** 2022-05-23
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03121352

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03121352, "Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03121352. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*